investigational

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

1 month ago
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary diseaseInvestigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

1 month ago
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathyERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

1 month ago